Revolutionizing Drug Discovery
for Animal Health with
AI-driven Peptide Design
Livestock and companion animals
Scroll

Animal Health Industries avoid full drug development due to high risk, losing a multi-billion market opportunity.

Industry Problem Overview
MOLECULE
DISCOVER
LAB
VALIDATION
POC
VALIDATION
SCALE-UP
PROCESS
CLINICAL
TRIAL
REGULATORY
PROCESS

Drug Discovery

Drug Development

TIME ~0 YEARS
COST ~ USD 0 M
FAIL RATE ~0%
What if the risk of discovering a new drug were lower
?
WHAT IF THE RISK
OF DISCOVERING
A NEW DRUG
WERE LOWER

Peptidus enables new drugs by transforming the drug discovery process

Peptidus Drug Discovery Platform
Peptidus Drug Discovery Platform
Peptidus
TARGET
DEFINITION
LAIKA Platform
IN SILICO
PEPTIDE DESIGN
IN VITRO
VALIDATION
IN VIVO
VALIDATION
POC
VALIDATION
New Drug
0x
FASTER
0x
LESS COSTLY
0x
SUCCESS RATE
Industry
TARGET
DEFINITION
MOLECULAR SCREENING
IN VITRO
VALIDATION
IN VIVO
VALIDATION
POC
VALIDATION
Industry Drug Discovery Process

We built LAIKA, a proprietary, multi-layered AI platform purpose-built for peptide drug discovery in animal health.

Our three strategies work simultaneously to deliver the most effective peptides

Peptidus Biotech Active
LAIKA
Galactic Dog
LAIKA Platform Flow

Powered by proprietary and public peptide databases.

Peptidus Database
Peptidus' exclusive
peptides database
Public's peptides
database
HOW OUR PEPTIDES ARE DESIGNED
Amino acid sequences

Define amino acid sequences that drive the desired biological effect.

Peptide chains

Assemble peptide chains optimized for predicted activity and stability.

3D peptide conformation

Refine the 3D peptide conformation to precisely fit the target molecule.

HOW OUR TECHNOLOGY WORKS

Loops Strategy (MRL)

Iterative loop modeling to build peptide structures.

Embedding Strategy

Generates sequences from target-surface embeddings.

Diffusion Methods

Applies diffusion models to design full peptide folds in a single step.

Selection of the best candidates for lab tests

Molecular Dynamics

Validate and select top peptide candidates through Molecular Dynamics simulations.

OUR PIPELINE HAS 10 PEPTIDES BEING DEVELOPED TARGETING LIVESTOCK & COMPANION ANIMALS

Pipeline
TARGET
DEFINITION
LAIKA
AI-PLATFORM
IN VITRO
VALIDATION
IN VIVO
VALIDATION
POC
VALIDATION
IP
LICENSING
bull
Mastitis
Patent filed
dog
Derma-Healing
Patent filed
dog
Weight-loss
bull
Injectable AMP
dog
Atopic dermatitis
bull chicken dog
>5 assets

Our pipeline is continuously shaped in collaboration with global and regional animal health leaders

Business Model

We operate under a licensing model that turns innovation into scalable revenue in the USD 50 billion animal health market.

Business Model
TARGET
DEFINITION
LAIKA Platform
IN SILICO
PEPTIDE DESIGN
IN VITRO
VALIDATION
IN VIVO
VALIDATION
POC
VALIDATION
IP
LICENSING
CLINICAL
TRIAL
REGULATORY
PROCESS
LAUNCH
& SALES
Upfront Upfront
Royalties Royalties

Our pipeline is continuously shaped in collaboration with global and regional animal health leaders

Our Team

Our team combines a large experience on peptide development, animal health market and deep tech development

Bernardo Petriz

Co-Founder · CEO

Bernardo Petriz, Ph.D

Octávio Franco

Co-Founder · CSO

Octávio Franco, Ph.D

Rodrigo Ferreira

Co-Founder · COO

Rodrigo Ferreira, MBA

Lucas Delgado

Head of Finance Strategy

Lucas Delgado, MBA

Danieli Buccini

R&D

Danieli F. Buccini, Ph.D.

Lucas Lima

Bioinformatics

Lucas Lima, Ph.D.

Mariana Maximiano

R&D

Mariana Maximiano, Ph.D.

Advisors

Rinse Boersma

Global Market Advisor

Rinse Boersma, MSc

César de la Fuente

Scientific Advisor

César de la Fuente, Ph.D

Awards & Recognition

Parque Tecnológico de Brasília

Send a message

✓ Message sent! We'll get back to you soon.